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ABSTRACT: Expanding the chemical space and simulta-
neously ensuring synthetic accessibility is of upmost
importance, not only for the discovery of eﬀective binders for
novel protein classes but, more importantly, for the develop-
ment of compounds against hard-to-drug proteins. Here, we
present AutoCouple, a de novo approach to computational
ligand design focused on the diversity-oriented generation of chemical entities via virtual couplings. In a benchmark application,
chemically diverse compounds with low-nanomolar potency for the CBP bromodomain and high selectivity against the BRD4(1)
bromodomain were achieved by the synthesis of about 50 derivatives of the original fragment. The binding mode was conﬁrmed
by X-ray crystallography, target engagement in cells was demonstrated, and antiproliferative activity was showcased in three
cancer cell lines. These results reveal AutoCouple as a useful in silico coupling method to expand the chemical space in hit
optimization campaigns resulting in potent, selective, and cell permeable bromodomain ligands.
■ INTRODUCTION
The druglike chemical space is estimated at 1060 organic
molecules, but only 100 million have been synthesized to date,
and an even smaller fraction thereof is commercially available.1,2
Libraries of purchasable molecules are biased toward certain
classes of targets, in particular G-protein-coupled receptors and
kinases.3,4 Repositories of pharmaceutical companies consist of
106 to 107 compounds which barely scratch the surface of
chemical space. Success in high-throughput screening ulti-
mately relies on the screening library:5−7 the exploration of
chemical space that is not biased toward already investigated
targets is decisive not only for the discovery of eﬀective binders
for novel protein classes but, more importantly, for the
development of compounds against protein targets that are
hard-to-drug.8−11 Classical de novo strategies can potentially
populate new areas of chemical space,12−16 and thus, programs
have been developed to disconnect molecules following
retrosynthesis rules17,18 producing fragments that can be used
later on to construct new libraries.19 Nevertheless, signiﬁcant
challenges when reaching the synthesis stage might prevent
those new molecular entities from being prepared and,
ultimately, becoming useful chemical probes.13 In addition,
time pressure in drug-discovery campaigns demands new tools
to improve the identiﬁcation of hits and streamline their
optimization into lead compounds.20 Computational tools for
de novo generation of molecular entities via virtual couplings
have been reported.21−24 The method proposed here, called
AutoCouple, distinguishes itself by starting from a set of
available building blocks that are assembled via virtual organic
reactions in such a way that, at the coupling step, the reaction
partners are parsed automatically and are coupled only if no
undesired group is contained (e.g., groups that would require
additional protection steps or lead to cross reactivity products
are discarded). As such, AutoCouple generates libraries of
compounds that are, ideally, synthesizable in one step.
Bromodomains are protein modules that bind acetylated
lysine (KAc) residues in histone tails and other proteins.
Among the 61 known human bromodomains,25 the BET
family, in particular BRD4(1) (the ﬁrst bromodomain of the
protein called BRD4), has been widely targeted because of its
involvement in cancer, type 2 diabetes, and cardiovascular
diseases.26−30 Several small molecule ligands of BET
bromodomains are currently in clinical trials, which highlights
the potential of regulating post-transcriptional modiﬁcations of
histone tails in the current landscape of drug discovery.31−34 In
contrast, selective and potent bromodomain ligands, aiming to
unravel the biological implications of bromodomains outside
the BET family, have only recently started to be devel-
oped.35−54 In particular, the bromodomain of CBP (the
epigenetic reader of the cyclic AMP response element binding
protein) is an interesting target due to its key role in several
diseases including cancer and neurological disorders.55 Despite
recent eﬀorts toward developing novel and selective CBP
bromodomain inhibitors, the chemotypes that are able to act as
KAc mimic are still rather limited and, except for GNE-781,
demand exquisite absolute stereocontrol, thus complicating
their synthetic accessibility (Figure 1A).56−67
Our groups have recently reported the fragment-based
design68,69 of acetyl benzene derivatives as selective nanomolar
Received: August 29, 2017
Published: February 7, 2018
Research Article
Cite This: ACS Cent. Sci. 2018, 4, 180−188
© 2018 American Chemical Society 180 DOI: 10.1021/acscentsci.7b00401
ACS Cent. Sci. 2018, 4, 180−188
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
CBP bromodomain ligands.70,71 Compound 1 (Figure 1B),
bearing a benzoic acid moiety, proved to be a synthetically
accessible molecule with an equilibrium dissociation constant
(Kd) of 770 nM for the CBP bromodomain and good selectivity
over BRD4(1) (selectivity >65-fold according to the ratio of Kd
values). The overlap of the crystal structures of the complex of
compound 1 with the CBP bromodomain and the structure of
BRD4(1) (Figure 1C) shows that the selectivity is due to the
steric clash between the benzoate group and the Trp81 side
chain of the so-called WPF triad of BRD4(1). Further
development of this compound was not pursued given its
lack of target engagement in cells, likely due to the negative
eﬀect of the carboxylate on the compound’s permeability, a
commonly encountered problem in medicinal chemistry
optimization campaigns.72−74 We thus set out to identify new
chemotypes enabling interactions at the outer part of the
binding site of the CBP bromodomain (Arg1173 and/or the so-
called ZA loop) that could potentially translate into ligands
with improved potency, selectivity, and cell permeability
compared to hit 1.
To this end, we sought to establish an eﬃcient method for
growing fragments into potent and selective ligands taking
chemical accessibility into account at the outset of the
computation.75,76 This early on synthesis oriented approach
Figure 1. (A) List of current nM inhibitors of the CBP bromodomain.44,56−58,60 Dissociation constant (Kd) determined by isothermal titration
calorimetry (ITC). Half-maximal inhibitory concentration (IC50) determined by time-resolved ﬂuorescence resonance energy transfer (TR-FRET).
Selectivity for CBP over BRD4(1) bromodomains (S1) determined by the ratio of Kd or IC50 values. (B) Crystal structure of the CBP bromodomain
(cyan) in complex with compound 1 (green) (PDB code: 4TQN).70,71 The acetyl benzene moiety acts as a KAc mimic interacting directly and
through a water molecule with the side chains of the conserved residues Asn1168 and Tyr1125, respectively. The carboxylate function of the tail
group forms a salt bridge with the guanidinium of Arg1173. The amide linker is involved in two water-bridged hydrogen bonds with the CBP
bromodomain. (C) Overlay of the complex of compound 1 (green) with the CBP bromodomain (cyan) and the structure of BRD4(1) (4PCI)
shows that the selectivity is due to bumping of the benzoate into the Trp81 side chain (red) of the so-called WPF triad of BRD4(1).
Figure 2. Schematic representation of AutoCouple. A headgroup (here the KAc mimic is shown in orange) is virtually coupled to commercially
available building blocks. The resulting library is ﬁltered out to remove any protein-reactive functionalities and subsequently docked while
maintaining key interactions of the headgroup inside the target’s binding site. The compounds are ranked according to binding energy calculated by a
force ﬁeld with continuum electrostatic solvation.
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would confer on our method the possibility to overcome the
limitations of previously released software tools which typically
suggest hard-to-synthesize molecules, hampering follow-up
medicinal chemistry eﬀorts. Here, we present the realization
of this concept with AutoCouple, a novel approach to de novo
computational ligand design that focuses on the diversity-
oriented generation of chemical entities via virtual chemical
couplings. AutoCouple is the ﬁrst fragment-growing software
tool that generates synthetically accessible molecules with a
force ﬁeld based prediction of their binding energy without any
ﬁtting parameter. Its operative and pragmatic value has been
demonstrated by the discovery of novel chemical blueprints
which translated into nM potent and cell-permeable inhibitors
of the CBP bromodomain with high selectivity over BRD4(1).
Further, the preliminary biological evaluation of cell permeable
ligands points toward the potential use of these compounds to
unravel the role of CBP in several types of solid tumors and
hematological malignancies.77
■ RESULTS AND DISCUSSION
Implementation of AutoCouple and Application to
CBP Bromodomain. First, a suite of Python scripts78,79 was
assembled (see section 1 in the Supporting Information) to
generate a virtual library from commercially available reagents
by a set of coupling reactions suited for medicinal chemistry
(Figure 2). Three reactions were established based on the
following criteria:5,80 (a) the robustness of the intended
chemical coupling, (b) the applicability to a wide variety of
reactants, (c) the proven relevance/use in drug-discovery
campaigns. The acetyl benzene moiety within 1 was retained as
Scheme 1. AutoCouple Results for the CBP Bromodomain Using (A) Amide Condensation, (B) Buchwald−Hartwig Amination,
and (C) Suzuki Cross-Coupling Reactions from Aniline (2), Bromobenzene (3), and Aryl Boronic Ester (4) as “Headgroups”,
Respectivelya
aKd values (μM) were determined by a competition binding assay in duplicates (BROMOscan).
88 IC50 values for compound 16 are indicated in
purple and were determined by ampliﬁed luminescent proximity homogeneous assay (Alpha) screen technology (Reaction Biology). Ligand
eﬃciency (LE) values refer to the CBP bromodomain. Selectivity for CBP over BRD4(1) bromodomains (S1) determined by the ratio of Kd or IC50
values. (D) Chimerization of compounds 5−7. The growing vectors (green arrows) of the diﬀerent coupling strategies show the similarity between
the amide and the C−C coupled products compared to the amine linker in orienting the tail group.
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the KAc mimic (from now on referred to as “headgroup”), and
we thus decided to explore the chemical space of the “tail
group” adjacent to the KAc mimic.
First, commercially available building block libraries were
generated, followed by coupling in silico to the KAc mimic in
compound 1. Aniline 2, bromobenzene 3, and aryl boronic
ester 4 were selected as “headgroups” for amide condensation,
Buchwald−Hartwig amination, and Suzuki cross-coupling,
respectively (Schemes 1A, 1B, and 1C respectively). For the
tail, a library of ∼270,000 commercially available compounds
was sorted according to chemical functionalities. A series of
ﬁlters were applied to limit the ﬁnal molecular complexity and
to discard molecular patterns known to react non-speciﬁcally
with most proteins81,82 as well as heavy metals containing
molecules. Moreover, to avoid redundancies, any building
blocks with the same CAS number were merged. Considering
that chemical couplings imply an increase in the molecular
complexity (except for cleavage reactions),22 and that the
coupling products should preferably satisfy the Lipinski rule of
5 for druglikeness, building blocks meeting any of the following
criteria were discarded: (a) >5 rotatable bonds; (b) number of
heavy atoms (= non-hydrogen) smaller than 3 or larger than
35; (c) >2 chiral centers. Each virtual reaction was also encoded
to discard any building block that contained undesired chemical
functionalities that would require a protecting group or lead to
cross-reactivity problems. For instance, for the Buchwald−
Hartwig coupling, the amine building blocks containing a halide
(which would ultimately lead to self-condensation) were not
kept for the virtual reactions.
A total of ∼70,000 virtual compounds were generated:
32,000 carboxylic amides (A), 19,000 anilines (B), and 19,000
C−C coupled ligands (C). Five independent docking
campaigns were carried out with libraries A, B, and C using
the CBP bromodomain structures 3P1C, 4TQN, and 4NYX
(see section 1.3 in the Supporting Information). Multiple
crystal structures were used because of the ﬂexibility of the
Arg1173 side chain and the rigid-protein protocol employed for
docking by the open-source software rDock.83 The acetyl
benzene was initially oriented in the binding site to mimic the
KAc residue as observed in the crystal structure and then
underwent ﬂexible docking. The poses obtained by docking
were subsequently minimized using the CHARMM program84
and the CHARMM36/CGenFF force ﬁeld85,86 with evaluation
of desolvation eﬀects in the continuum dielectric approxima-
tion.87 Receiver operating characteristic (ROC) curves using
known positive controls70,71 were plotted as to ensure the
ability of the force ﬁeld and implicit solvent approximation
(ﬁnite-diﬀerence Poisson) to prioritize active ligands.
Synthesis of de Novo Ligand Binders: Potency,
Selectivity, and Binding Mode Validation. Overall, 53
top-ranking compounds were synthesized (Scheme 1A−C) and
a competition binding assay (BROMOscan)88 was used to
measure dissociation constants (for exhaustive data on all
synthesized ligands, see section 2 in the Supporting
Information). Using amide coupling for fragment assembly
enabled us to identify arylsulfonamides, -acetamides, and
-thiazoles with diverse substitution patterns (5−8) as suitable
motifs to replace the original benzoate “tail group”. These de
novo synthesized ligands displayed comparable or even
improved levels of potency and selectivity compared to those
previously observed for 1. Compound 5 showed not only a 4-
fold improvement in potency (Kd = 200 nM) but also a
remarkably high selectivity (>250-fold) against BRD4(1).
Furthermore, the “amide-coupling” campaign resulted in 33
synthesized molecules, four of which display submicromolar
aﬃnity (compounds 5−8, Scheme 1A), 17 are low micromolar
binders (1.2−6.5 μM), and 10 have Kd values between 10 μM
and 45 μM (see Figure S1). Compounds stemming from both
Buchwald−Hartwig amination (9, 10) and Suzuki cross-
coupling (11−15) consistently showed improved aﬃnities
and good selectivity while oﬀering additional motifs (cyclic and
linear alkylsulfonamides, diester, tetrazoles) to the portfolio of
“tail groups” for CBP ligands (Scheme 1B,C).
Interestingly, ﬁve out of 10 molecules synthesized by Suzuki
cross-couplings are nanomolar binders with Kd values ranging
from 85 to 840 nM (Scheme 1C, compounds 11−15), thus
conﬁrming the ability of AutoCouple to identify good binders.
The comparison between the three series of compounds (A,
B, C) conﬁrms that the amide linker does not contribute
signiﬁcantly to binding aﬃnity, which is consistent with
previous molecular dynamics simulations that showed rotations
of the amide group on the 100 ns time scale.70,89 In addition,
the analysis of the growing vectors of the three coupling
strategies reveals interesting trends. As shown by the green
arrows (growing vectors) in Scheme 1, a geometric similarity
between the amide and the C−C coupled products (A, C) can
be found, in line with the consistently higher potency observed
for the compounds obtained via these two reactions compared
to those introducing the amine linker (B).
The preparation of an analogue of compound 1 bearing a
triazole as KAc mimic (Table S2) turned out to be more
selective for BRD4(1) over CBP, suggesting that the selectivity
Figure 3. (A) Structural alignment of the crystal structure of the CBP bromodomain (cyan) in complex with ligand 16 (green) (PDB code 5NLK)
and the pose of ligand 7 (yellow) as predicted by docking into the CBP structure 4NYX (Arg1173 side chain in yellow). (B) Overlay of the complex
of compound 16 (green) with the CBP bromodomain (cyan) and the structure of BRD4(1) (4PCI) shows that the selectivity is due to bumping of
the phenyl into the Trp81 side chain (red) of the so-called WPF triad of BRD4(1).
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can possibly arise from the KAc mimic moiety.90 AutoCouple
was therefore further validated through a virtual-coupling
campaign to design BRD4(1) inhibitors (detailed information
is available in section 3 in the Supporting Information).
Hybridization Strategies. Aiming to further improve the
aﬃnity of these compounds, we decided to combine the best
performing motifs in the amide-coupling campaign (acetamide
5, dimethoxybenzene 6, and furan 7) into compounds 16−18.
This hybridization approach resulted in additional low
nanomolar CBP ligands (Scheme 1D). Remarkably, compound
16 shows an aﬃnity for the CBP bromodomain higher by a
factor of more than 10,000 with respect to the aﬃnity for the
BRD4(1) bromodomain while still exhibiting an excellent
ligand eﬃciency for the target of 0.31 and 0.32 kcal mol−1 per
non-hydrogen atom (according to BROMOscan and Al-
phaScreen, respectively) in line with recommendations for
maintaining druglike properties throughout the optimization
process.91,92
The crystal structure of CBP in complex with ligand 16
(PDB code 5NLK) could be obtained, conﬁrming that the
binding mode predicted by AutoCouple is correct (Figure 3A):
the furan ring of compound 16 is at favorable van der Waals
distance to the Pro1106 side chain as predicted by the docked
pose of the parent compound 7. The overlap of the crystal
structure of the CBP/ligand 16 complex with the BRD4(1)
structure shows steric conﬂicts with the Trp81 side chain
(Figure 3B), which explains its high selectivity.59,60 Compound
16 was further proﬁled via a BROMOscan against a panel of
bromodomains covering all subfamilies (Figure 4E). While the
strong binding to CREBBP and EP300 could again be
conﬁrmed, only moderate aﬃnity for the bromodomains of
CECR2 (the bromodomain of the cat eye syndrome critical
region protein 2) and TAF1(2) (the second bromodomain of
human transcription initiation factor TFIID subunit 2) was
observed.93
Target Engagement in Cells and Preliminary Bio-
logical Evaluation. The target engagement of some of these
ligands and thus their cell permeability were evaluated by
means of a ﬂuorescence recovery after photobleaching (FRAP)
assay.94 In human osteosarcoma U2OS cells, compounds 6, 7,
13, 16, and 17 at a concentration of 1 μM showed signiﬁcant
displacement of the GFP-fused CBP bromodomain from
chromatin. In particular, compound 16, which displayed the
highest aﬃnity for the CBP bromodomain in the biochemical
assay (Kd = 35 nM), showed also the strongest eﬀect in the
FRAP assay (Figure 4A,B). The compounds’ purity was
evaluated by peak integration of the UV/visible HPLC
chromatograms for compounds 6 (99%), 7 (94%), 13 (99%),
16 (97%), and 17 (92%) (see section 11 in the SI).
Compound 16 was further tested in cellular proliferation
assays. Three cell lines known to be sensitive to CBP
bromodomain inhibition, i.e., LP1 (multiple myeloma),
Kasumi, and HL-60 (acute myeloblastic leukemia),59,95 were
selected as well as nontransformed primary ﬁbroblast MRC5.96
The MRC5 cells are used as control as they are noncancer cells
and with limited lifespan caused by replicative senescence.97
The resazurin assay was employed with compound incubation
for 72 h (LP1, Kasumi, and MRC5; Figure 4C) or 144 h (LP1,
Kasumi, and HL-60; Figure S9).98 Remarkably, compound 16
selectively inhibited the proliferation of the three cancer cell
lines, but was not toxic in MRC5 cells (GI50 > 20 μM) (Figure
4C, Figures S8 and S9). Since CBP and EP300 regulate the
transcription of the lymphocyte-speciﬁc transcription factor
IRF4 and the IRF4 target gene c-MYC in myeloma cells,59,60
we investigated the transcription of IRF4 and c-MYC in the
LP1 cell line using RT-qPCR (reverse transcription quantitative
Figure 4. (A,B) FRAP assay for compounds 6, 7, 13, 16, and 17; U2OS cells were transfected with plasmids encoding GFP-fused to wild-type (WT)
or mutant (N1168F) multimerized CBP bromodomain, with or without 2.5 μM suberoylanilide hydroxamic acid (SAHA, a deacetylase inhibitor)
and indicated compounds at a concentration of 1 μM. (A) Fluorescent recovery curves after photobleaching (normalized to the intensity before
bleaching). (B) Half-times of the ﬂuorescence recovery (t1/2) (n ≥ 7 cells per group, error bars: standard error of the mean). The recovery t1/2 of the
compound-treated cells was compared to that of DMSO-treated cells (bar on the left) within the same experiment setup using Mann−Whitney test.
**, P < 0.01; ***, P < 0.001; ****, P < 0.0001. (C) Concentration of compound 16 that results in 50% growth inhibition (GI50). LP1 and Kasumi
are human tumor cell lines while the nontransformed ﬁbroblast MRC5 is a negative control. GI50 values were determined by a resazurin assay after
72 h compound incubation. (D) Dose-dependent inhibition of IRF4 and c-Myc mRNA transcription (RT-qPCR) by compound 16 in LP1 cells after
6 h of treatment. (C, D) Values represent the mean of at least three biological replicates ± SD. The curves are ﬁts by a four-parameter logistic
function. (E) Selectivity proﬁle of compound 16 in a panel of bromodomains representing all subfamilies of human bromodomains. The Kd values
were determined by a competition binding assay.88 (F, G) FRAP assay for compound 16 in U2OS cells transfected with a plasmid encoding GFP-
BRD4. Cells were treated with compound 16 (1 μM) or a BRD4 ligand JQ1 (0.1 μM). (F) Fluorescent recovery curves after photobleaching
(normalized to the intensity before bleaching). (G) t1/2 in the FRAP assay of F (n ≥ 7 cells per group, error bars: standard error of the mean, Mann−
Whitney test; ***, P < 0.001; n.s., not signiﬁcant).
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polymerase chain reaction). The dose−response curves showed
that the mRNA levels of IRF4 and c-MYC were reduced after
incubation for 6 h with compound 16 (Figure 4D). Since the
inhibition of BRD4 bromodomains also has a strong eﬀect on c-
MYC expression,99 one could argue that the c-MYC inhibition
by compound 16 arises from a weak binding to the BRD4
protein. To address this issue, we evaluated the BRD4
engagement in cells by FRAP. Compound 16 at 1 μM showed
no eﬀect on the ﬂuorescence recovery time (Figure 4F,G), thus
conﬁrming the potential of compound 16 as a useful tool to
unravel the speciﬁc role of CBP bromodomain in disease.
■ CONCLUSIONS
A de novo design approach based on virtual chemical reactions
starting from commercially available building blocks (Auto-
Couple) has been developed and successfully applied to the
identiﬁcation of potent and selective bromodomain ligands.
This novel approach makes full use of the three-dimensional
structure of the protein target and calculates the binding energy
by molecular mechanics (transferable force ﬁeld including
electrostatic solvation by the Poisson equation) without any
ﬁtting parameter. Thus, AutoCouple is a fragment-growing
program that generates synthetically accessible molecules with
an accurate and eﬃcient prediction of their binding energy. Our
in silico guided medicinal chemistry optimization represents a
very eﬃcient strategy to expand the chemical diversity while
swiftly acquiring knowledge on previously unexplored areas of
chemical space for the target of choice.
AutoCouple has been benchmarked on the CBP bromodo-
main taking an existing hit as starting point for a ligand
optimization campaign. While only potency and synthetic
accessibility were encoded in the design working principles of
AutoCouple, highly potent and selective ligands with improved
solubility and cell permeability have been identiﬁed, thus
underpinning the importance of chemical diversity in tackling
properties that are hard to predict with existing softwares. Hit
expansion by AutoCouple resulted in compound 16, a cell-
permeable ligand of the CBP bromodomain with low-
nanomolar potency and high selectivity against BRD4(1).
This probe represents a useful chemical tool to unravel the
individual role of CBP in several types of diseases including
cancer, inﬂammation, and hematological malignancies among
others. Further biological evaluation of these compounds and
application of AutoCouple to other protein targets are currently
ongoing in our laboratories.
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(58) Taylor, A. M.; Côte,́ A.; Hewitt, M. C.; Pastor, R.; Leblanc, Y.;
Nasveschuk, C. G.; Romero, F. A.; Crawford, T. D.; Cantone, N.;
Jayaram, H.; Setser, J.; Murray, J.; Beresini, M. H.; de Leon Boenig, G.;
Chen, Z.; Conery, A. R.; Cummings, R. T.; Dakin, L. A.; Flynn, E. M.;
Huang, O. W.; Kaufman, S.; Keller, P. J.; Kiefer, J. R.; Lai, T.; Li, Y.;
Liao, J.; Liu, W.; Lu, H.; Pardo, E.; Tsui, V.; Wang, J.; Wang, Y.; Xu, Z.;
Yan, F.; Yu, D.; Zawadzke, L.; Zhu, X.; Zhu, X.; Sims, R. J.; Cochran,
A. G.; Bellon, S.; Audia, J. E.; Magnuson, S.; Albrecht, B. K. Fragment-
Based Discovery of a Selective and Cell-Active Benzodiazepinone
CBP/EP300 Bromodomain Inhibitor (CPI-637). ACS Med. Chem.
Lett. 2016, 7, 531−536.
(59) Crawford, T. D.; Romero, F. A.; Lai, K. W.; Tsui, V.; Taylor, A.
M.; de Leon Boenig, G.; Noland, C. L.; Murray, J.; Ly, J.; Choo, E. F.;
Hunsaker, T. L.; Chan, E. W.; Merchant, M.; Kharbanda, S.;
Gascoigne, K. E.; Kaufman, S.; Beresini, M. H.; Liao, J.; Liu, W.;
Chen, K. X.; Chen, Z.; Conery, A. R.; Côte,́ A.; Jayaram, H.; Jiang, Y.;
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